News
HRTX
1.810
-0.55%
-0.010
Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors
Seeking Alpha · 1d ago
Weekly Report: what happened at HRTX last week (0902-0906)?
Weekly Report · 3d ago
HERON THERAPEUTICS ANNOUNCES APPOINTMENT OF BRETT FLESHMAN AS CHIEF BUSINESS OFFICER
Reuters · 09/03 12:00
Press Release: Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Dow Jones · 09/03 12:00
Weekly Report: what happened at HRTX last week (0826-0830)?
Weekly Report · 09/02 11:10
Biotech Stocks Facing FDA Decision In September 2024
NASDAQ · 09/02 02:35
Weekly Report: what happened at HRTX last week (0819-0823)?
Weekly Report · 08/26 11:08
Weekly Report: what happened at HRTX last week (0812-0816)?
Weekly Report · 08/19 10:56
Weekly Report: what happened at HRTX last week (0805-0809)?
Weekly Report · 08/12 10:58
Heron Therapeutics Price Target Maintained With a $5.00/Share by Needham
Dow Jones · 08/07 10:31
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Benzinga · 08/07 10:21
Heron Therapeutics: Poised for Profitability Amid Growth Catalysts
TipRanks · 08/07 09:55
HERON THERAPEUTICS, INC. FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024
Press release · 08/07 02:50
HRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024
Investorplace · 08/07 00:59
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
NASDAQ · 08/06 23:30
Heron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Reuters · 08/06 22:05
Heron Therapeutics GAAP EPS of -$0.06 misses by $0.02, revenue of $36.02M beats by $0.13M
Seeking Alpha · 08/06 20:45
HERON THERAPEUTICS INC SEES FY PRODUCT REVENUES $138.0 TO $158.0 MILLION
Reuters · 08/06 20:05
*Heron Therapeutics 2Q Loss/Shr 6c >HRTX
Dow Jones · 08/06 20:05
Press Release: Heron Therapeutics Announces -3-
Dow Jones · 08/06 20:05
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.